Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-060580
Filing Date
2025-04-30
Accepted
2025-04-30 07:40:10
Documents
20
Period of Report
2025-06-23

Document Format Files

Seq Description Document Type Size
1 DEF 14A hlvx-20250429.htm   iXBRL DEF 14A 720829
2 GRAPHIC img92602099_0.jpg GRAPHIC 24699
3 GRAPHIC img92602099_1.jpg GRAPHIC 6339
4 GRAPHIC img92602099_2.jpg GRAPHIC 24699
5 GRAPHIC img92602099_3.jpg GRAPHIC 140083
6 GRAPHIC img92602099_4.jpg GRAPHIC 24699
7 GRAPHIC img92602099_5.jpg GRAPHIC 6339
8 GRAPHIC img92602099_6.jpg GRAPHIC 1221747
9 GRAPHIC img92602099_7.jpg GRAPHIC 539759
  Complete submission text file 0000950170-25-060580.txt   6133393

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT hlvx-20250429.xsd EX-101.SCH 8295
22 EXTRACTED XBRL INSTANCE DOCUMENT hlvx-20250429_htm.xml XML 5216
Mailing Address 321 HARRISON AVE, SUITE 500 BOSTON MA 02118
Business Address 321 HARRISON AVE, SUITE 500 BOSTON MA 02118 (617) 213-5054
HilleVax, Inc. (Filer) CIK: 0001888012 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41365 | Film No.: 25891023
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)